Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Azacitidine × CNS × Clear all

Phase

Phase 1 4 Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 151 Myeloid 58 Lymphoid 20 Thoracic 6 Gastrointestinal 5 Classical hematology 5 Breast 4 Genitourinary 3 Sarcoma 2 Plasma cell 2 Gynecologic 2 Head & Neck 1 Dermatologic 1 CNS 1

Conditions

Interventions

Temozolomide 217 Radiotherapy 123 Bevacizumab 121 Etoposide 56 Cyclophosphamide 55 Carboplatin 55 Magnetic Resonance Spectroscopy 48 Irinotecan 48 Cisplatin 37 pembrolizumab 36 Vincristine 33 Radiosurgery 32 Nivolumab 30 Filgrastim 30 Specimen Handling 25 Topotecan 24 Radiation 24 sargramostim 23 Lomustine 23 Doxorubicin 23 Carmustine 23 Erlotinib Hydrochloride 21 Thiotepa 19 Peripheral Blood Stem Cell Transplantation 19 Chemotherapy, Adjuvant 19 Granulocyte-Macrophage Colony-Stimulating Factor 18 Surgical Procedures, Operative 17 Melphalan 17 Ipilimumab 17 Everolimus 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03666559 2024-02-29

AGIR

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡